Medical
UK
Europe
NovoCure
$70.489876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$70.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.09 (1.57%) Today
$0.00 (0.00%) As of 4:06 PM EDT after-hours
Why Robinhood?
You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!
About NVCR
NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Employees
598
Headquarters
St. Helier, Jersey
Founded
2000
Market Cap
6.64B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
697.85K
High Today
$71.79
Low Today
$69.90
Open Price
$71.20
Volume
656.72K
52 Week High
$72.59
52 Week Low
$26.02
Collections
Medical
UK
Europe
Health
Cancer Prevention
Technology
2015 IPO
Price Paid on Robinhood
70% Higher
Right Now
52 Week Low
$26.02
Average Price Paid
$41.52
52 Week High
$72.59
Analyst Ratings
67%
of 6 ratings
Buy
67%
Hold
33%
Sell
0%
NVCR Earnings
-$0.23
-$0.18
-$0.12
-$0.07
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.07 per share
Actual
Available Jul 25, Pre-Market